Bone morphogenetic protein‐2 against iliac crest bone graft for the posterolateral fusion of the lumbar spine: A meta‐analysis

• Published in: International journal of clinical practice (Esher) Vol. 75; no. 4; pp. e13911 - n/a
• Main Authors: Wu, Zhenyu, Zhou, Bo, Chen, Liang, Wang, Xiaofeng, Abdelrahim, Mohamed E. A., Wei, Cheng
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.04.2021
• Subjects: Autografts; Bone grafts; Bone surgery; Bone Transplantation; Frogs; Humans; Iliac crest; Ilium - surgery; Lumbar Vertebrae - surgery; Meta-analysis; Proteins; Skin & tissue grafts; Spinal Fusion; Spine (lumbar); Treatment Outcome
• ISSN: 1368-5031; 1742-1241; 1742-1241
• DOI: 10.1111/ijcp.13911

Background The impact of bone morphogenetic protein‐2 compared to autologous iliac crest bone graft to improve fusion rates for the posterolateral fusion of the lumbar spine remains inconclusive. This meta‐analysis was performed to evaluate this relationship. Methods A systematic literature search up to May 2020 was performed and 14 studies were detected with 1516 subjects with 789 of them were bone morphogenetic protein‐2 and 727 of them were autologous iliac crest bone graft. They reported relationships between bone morphogenetic protein‐2 and autologous iliac crest bone graft on fusion rates for the posterolateral fusion of the lumbar spine. Odds ratio (OR) with 95% confidence intervals (CIs) was calculated comparing the bone morphogenetic protein‐2 or autologous iliac crest bone graft on the posterolateral fusion of the lumbar spine risks using the dichotomous and continuous method with a random‐ or fixed‐effect model. Results Bone morphogenetic protein‐2 had significantly higher fusion rates (OR, 4.19; 95% CI, 2.82‐6.20, P < .001); lower surgery time (OR, −26.64; 95% CI, −38.71 to −14.57, P < .001); lower blood loss (OR, −92.84; 95% CI, −131.71 to −53.97, P < .001); lower additional surgical procedures (OR, 0.46; 95% CI, 0.31‐0.69, P < .001) and higher Oswestry Disability Index (OR, 1.49; 95% CI, 0.02‐2.97, P = .05) compared to autologous iliac crest bone graft. However, no significant difference was found between bone morphogenetic protein‐2 and autologous iliac crest bone graft in non‐union rates (OR, 0.34; 95% CI, 0.08‐1.53, P < .001); hospitalisation days (OR, −0.21; 95% CI, −0.48 to 0.07, P = .14) and adverse events (OR, 0.78; 95% CI, 0.52‐1.16, P = .22). Conclusions Bone morphogenetic protein‐2 significantly had a higher fusion rate, lower surgery time, lower blood loss, lower additional surgical procedures and higher Oswestry Disability Index compared to autologous iliac crest bone graft. This relationship forces us to recommend bone morphogenetic protein‐2 for the posterolateral fusion of the lumbar spine to avoid any possible negative postoperative results.